SCHEMBL4351916

SCHEMBL4351916

CCCc1c(-c2ccc(OC)cc2)[nH]c2ccc(Oc3c(Br)cc(CCC(=O)O)cc3Br)cc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.51
F2 P00734 1/20 0.48
F10 P00742 1/20 0.48
MTNR1A P48039 4/20 0.48
MTNR1B P49286 4/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
HSD17B10 Q99714 2/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
THRA P10827 1/20 0.47
THRB P10828 1/20 0.47
HTR1A P08908 1/20 0.44
HTR1D P28221 1/20 0.44
SLC6A4 P31645 1/20 0.44
HTR7 P34969 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513504 0.94 PPARG (0.49) PPARGF2F10MTNR1AMTNR1B
SCHEMBL4528982 0.88 THRA (0.49) PPARGF2F10MTNR1AMTNR1B
SCHEMBL4349830 0.85 THRA (0.47) PPARGF2F10MTNR1AMTNR1B
SCHEMBL4518770 0.81 THRA (0.43) PPARGF2F10MTNR1AMTNR1B
SCHEMBL3990206 0.81 THRA (0.48) PPARGF2F10THRATHRB
SCHEMBL4525261 0.79 PPARG (0.43) PPARGMTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL4518871 0.78 THRA (0.48) PPARGF2F10KDM4EALDH1A1
SCHEMBL5859480 0.78 THRA (0.64) THRATHRB
SCHEMBL4517480 0.78 THRA (0.49) PPARGMTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL4532920 0.77 THRA (0.49) PPARGMTNR1AMTNR1BKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009080835-A1 THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING KARO BIO AB (SE) 2009-07-02 WO claimed
US-20090233979-A1 Indole Derivatives and Their Use as Thyroid Receptor Ligands KARO BIO AB (SE) 2009-09-17 US disclosed
US-20090233979-A1 Indole Derivatives and Their Use as Thyroid Receptor Ligands KARO BIO AB (SE) 2009-09-17 US disclosed
US-20090233979-A1 Indole Derivatives and Their Use as Thyroid Receptor Ligands KARO BIO AB (SE) 2009-09-17 US disclosed
WO-2009080835-A1 THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING KARO BIO AB (SE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233979-A1 Indole Derivatives and Their Use as Thyroid Receptor Ligands TSHR, TRHR, THRA PPARG 195/4885F2 1771/4885F10 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.